JetBlue ends another airline partnership, benefits will be affected
Just weeks after the airline company announced its departure from Hawaiian Airlines, it decided to also bid farewell to TAP Air Portugal.
The last day customers can book TAP Air Portugal flights to earn or redeem TrueBlue points, which are used to get cheaper or free flights on JetBlue or other bonuses, will be Sept. 30 of this year, according to a statement from the airline company.
The deadline to travel and submit any requests for retroactive TrueBlue points must also be completed on or for before this date.
Cash bookings made on TAP Air Portugal will not be affected.
'We apologize for any inconvenience,' JetBlue wrote.
The two airline companies launched their partnership in February, according to a JetBlue press release.
TAP Air Portugal offers over 1,000 weekly flights to 80 cities in 32 countries, including Portugal, North America, Central and South America, Africa and Europe, the statement adds.
More Business News
Judge allows Medicaid payments to flow to Planned Parenthood centers
Earls Kitchen + Bar to open new Boston Seaport restaurant in 2027
Holyoke Mall will reopen today after Friday shooting; suspect was shot in leg by police
How much trash does a courthouse produce? Inquiring bidders want to know in Springfield
Housing Court judge denies landlord's request to stay a rent reduction at Ludlow mobile home park
Read the original article on MassLive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
8 hours ago
Republican Rep. Bryan Steil booed defending Trump tariffs at Wisconsin town hall
In a rowdy town hall on Thursday night, Wisconsin Republican Rep. Bryan Steil was booed when he expressed support for President Donald Trump's trade policies. An attendee pressed Steil on Trump's tariffs against scores of U.S. trade partners. "I really feel that this is a terrible tax that's going to be placed on the citizens of the Unites States. I would like to know what dire economic circumstances put Trump in a position of deploying tariffs on over 190 countries?" the attendee asked, prompting applause from the crowd. "You have allowed him to do that and it's sad. So tell me the dire circumstances that triggered his tariff wars." Steil's response prompted loud boos from participants. "As we look at the broader tariffs back and forth with the administration, this really is, at its core needs to be, an opportunity to make sure other countries are treating the United States fairly," the congressman said. In the Elkorn town hall, the congressman was also pressed on other topics, including the impacts Trump's megabill will have on Medicaid and other services. The nonpartisan Congressional Budget Office estimated the cuts to Medicaid included the sweeping tax and spending cut bill, which Trump signed into law on July 4, will result in 10 million Americans losing health insurance. Responding to the event on X, Steil wrote "despite a handful of individuals attempting to disrupt the discussion, we had a great dialogue about the issues that matter most." He committed to holding future events. Some in the room were local protestors, ABC News affiliate WISN reported, including members of a group who last week carried a mock cardboard coffin to Steil's home to protest Medicaid cuts. Earlier this year, Rep. Richard Hudson, the chairman of the National Republican Congressional Committee, encouraged House Republicans to do more virtual events over in-person town halls after several House Republicans faced fiery constituents at in-person town halls. House Democrats are being challenged at their town halls, too, facing pushback on topics such as the response to the war in Gaza. Earlier this week, Illinois Rep. Bill Foster, a Democrat, hosted a town hall event where he was repeatedly interrupted by anti-war protesters.
Yahoo
10 hours ago
- Yahoo
Oppenheimer Initiates Outperform on Centene, Sees Turnaround Potential After Guidance Shock
Centene Corporation (NYSE:CNC) is one of the stocks that look extremely cheap on paper. On July 15, 2025, Oppenheimer initiated coverage with an Outperform rating, setting a fresh price target (exact target unspecified), positioning Centene as a recovery-backed opportunity amid healthcare volatility. This stand-out call emerged just weeks after Centene dramatically withdrew its 2025 earnings guidance, citing unexpected spikes in Medicaid and Marketplace costs, which led to a sharp stock drop of nearly 40% on July 2. Oppenheimer's move suggests confidence that management's repricing strategy and cost control efforts will turn the tide in the next 12–18 months. 15 States with the Best Healthcare in the US That guidance pull followed Centene's shocking second-quarter adjusted loss of $0.16 per share, missing estimates, even as revenue surged ~22% to $48.7 billion. The company's health benefits ratio soared to 93%, well above projections, highlighting the pressure from rising underwriting costs and ACA risk-adjustment shortfalls. Oppenheimer's initiation of Outperform in mid‑July, at what many view as rock-bottom valuation levels, anchors the narrative: here's a high-profile analyst betting on a turnaround after risk-adjustment shocks. Centene, based in St. Louis, delivers Medicaid, Medicare Advantage, ACA Marketplace, and correctional health services across the U.S., making it deeply exposed to federal policy shifts and enrollment dynamics. While we acknowledge the potential of CNC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
12 hours ago
- CNBC
Trump's drug price ultimatum sets pharma firms scrambling
Pharmaceutical firms are scrambling to respond to a fresh ultimatum from U.S. President Donald Trump demanding "binding commitments" to lower their drug prices stateside . The White House said Thursday that President Trump had sent letters to 17 major pharmaceutical firms outlining the steps they must take to lower the price of U.S. prescription drugs to "most favored nation" (MFN) levels by Sept. 29. They were told that if they "refuse to step up," the government will deploy every tool in its "arsenal to protect American families from continued abusive drug pricing practices," without stating what those measures could be. The companies to receive letters were AbbVie , Amgen , AstraZeneca , Boehringer Ingelheim, Bristol-Myers Squibb , Eli Lilly , EMD Serono, Roche' s subsidiary Genentech, Gilead , GSK , Johnson & Johnson , Merck , Novartis , Novo Nordisk , Pfizer , Regeneron and Sanofi . Healthcare stocks tumbled Friday, following broader market losses as investors digested Trump's amended trade tariffs. Shares of Wegovy-maker Novo Nordisk dropped 5% in early morning trade before paring losses to trade 1.3% lower at 11:15 a.m. London time (6:15 a.m. ET). Companies were informed that they must provide MFN prices to all Medicaid patients, the U.S. health program for low-income patients. They were also told not to offer medicines to other developed markets at better prices than those offered in the U.S., and that they should sell drugs directly to U.S. patients, thereby cutting out pharmacy middlemen known as pharmacy benefit managers (PBMs). Trump has long lambasted pharmaceutical firms for what he dubs are unfair pricing practices, previously saying that he planned to bring down U.S. prices by 80%. In May, the president signed an executive order to lower drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad under the MFN policy. The U.S. consistently pays the most in the world for many prescription drugs, due in part to the U.S.′ highly complex and fragmented reimbursement system and lack of national pricing control. The latest announcement comes as the pharmaceutical industry is also calling for clarity on potential industry-wide tariffs. Trump previously warned these could run as high as 200%. Many companies have nevertheless shared that they agree with some of Trump's concerns. AstraZeneca CEO Pascal Soriot said Tuesday that the Anglo-Swedish firm had been liaising closely with the U.S. administration over the MFN policy and investment in U.S. manufacturing more broadly. Last week, it announced plans to invest $50 billion in the U.S., following a slew of other pharma firms. "There are issues around prices. I personally believe the president is right to say price equalization should happen," Soriot told reporters on an earnings call. Vas Narasimhan, CEO of Swiss-headquartered Novartis, also said last month that the firm was pursuing an MFN policy to lower U.S. drug prices. JPMorgan analysts said in a note Friday that while the latest announcement was intended to serve as a stark warning, ongoing talks between with the U.S. administration could buy pharma firms some time to respond. "While the government's latest announcement may appear harsh, we think it is likely that the matter is being discussed to some extent between the companies and the government, and we believe no changes that would have a significant negative impact on pharmaceutical companies will occur in the short term," analysts led by Seiji Wakao said in a note to clients.
